Vilhelmas Bajoras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vilhelmas Bajoras has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Gintautas Bieliauskas
Copenhagen Univ Hosp, Heart Ctr, Rigshosp, Copenhagen, Denmark
3 shared publications- Giedrius Davidavicius
Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania
2 shared publications Ivan Wong
Copenhagen Univ Hosp, Heart Ctr, Rigshosp, Copenhagen, Denmark
2 shared publicationsLars Sondergaard
The Heart Centre, Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark
2 shared publications- Maarten Vanhaverbeke
Department of Cardiology, AZ Delta , Roeselare
2 shared publications Ole De Backer
The Heart Centre, Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark
2 shared publications
Latest Publications
- Open Access
Endocardial Left Atrial Appendage Occlusion in Atrial Fibrillation: Device Design, Clinical Evidence, and Postprocedural Antithrombotic Management
Background and Objectives: Atrial fibrillation is a major cause of ischemic stroke, and in patients with non-valvular atrial fibrillation the left atrial appendage is the predominant site of thrombus formation. Although oral anticoagulation remains the standard strategy for stroke prevention, long-term therapy may be limited by bleeding risk, prior major bleeding, contraindications, intolerance, or difficulty maintaining stable anticoagulation. Endocardial left atrial appendage occlusion (LAAO) has therefore emerged as an alternative strategy in selected patients. Its role continues to evolve with expanding device technologies, contemporary direct oral anticoagulant therapy, and ongoing randomized evidence. Materials and Methods: This narrative literature review summarizes current evidence on endocardial LAAO, focusing on device design, anatomical considerations, clinical outcomes, postprocedural antithrombotic therapy, and ongoing research directions. Results: Available devices differ substantially in sealing mechanism, fixation strategy, conformability, surface properties, and suitability for complex appendage anatomy. The Watchman and Amulet platforms remain the most extensively studied systems, whereas several CE-marked and investigational devices aim to improve anatomical adaptability, reduce peri-device leak and device-related thrombus, and simplify implantation. Randomized evidence supports LAAO as a non-inferior alternative to oral anticoagulation in selected populations, with potential reduction in late bleeding but persistent concerns regarding procedural risk, frailty, comorbidity burden, and patient selection. The optimal postprocedural antithrombotic regimen remains uncertain, with increasing interest in individualized strategies and short-term direct oral anticoagulant therapy when feasible. Current research is shifting toward next-generation devices, combined ablation–closure strategies, simplified imaging guidance, and evaluation of LAAO as both an alternative and an adjunct to oral anticoagulation. Conclusions: LAAO should currently be considered a selective rather than a universal strategy, requiring individualized assessment of thromboembolic risk, bleeding risk, anatomy, procedural safety, and comorbidity burden.
Open AccessEndocardial Left Atrial Appendage Occlusion in Atrial Fibrillation: Device Design, Clinical Evidence, and Postprocedural Antithrombotic Management
Background and Objectives: Atrial fibrillation is a major cause of ischemic stroke, and in patients with non-valvular atrial fibrillation the left atrial appendage is the predominant site of thrombus formation. Although oral anticoagulation remains the standard strategy for stroke prevention, long-term therapy may be limited by bleeding risk, prior major bleeding, contraindications, intolerance, or difficulty maintaining stable anticoagulation. Endocardial left atrial appendage occlusion (LAAO) has therefore emerged as an alternative strategy in selected patients. Its role continues to evolve with expanding device technologies, contemporary direct oral anticoagulant therapy, and ongoing randomized evidence. Materials and Methods: This narrative literature review summarizes current evidence on endocardial LAAO, focusing on device design, anatomical considerations, clinical outcomes, postprocedural antithrombotic therapy, and ongoing research directions. Results: Available devices differ substantially in sealing mechanism, fixation strategy, conformability, surface properties, and suitability for complex appendage anatomy. The Watchman and Amulet platforms remain the most extensively studied systems, whereas several CE-marked and investigational devices aim to improve anatomical adaptability, reduce peri-device leak and device-related thrombus, and simplify implantation. Randomized evidence supports LAAO as a non-inferior alternative to oral anticoagulation in selected populations, with potential reduction in late bleeding but persistent concerns regarding procedural risk, frailty, comorbidity burden, and patient selection. The optimal postprocedural antithrombotic regimen remains uncertain, with increasing interest in individualized strategies and short-term direct oral anticoagulant therapy when feasible. Current research is shifting toward next-generation devices, combined ablation–closure strategies, simplified imaging guidance, and evaluation of LAAO as both an alternative and an adjunct to oral anticoagulation. Conclusions: LAAO should currently be considered a selective rather than a universal strategy, requiring individualized assessment of thromboembolic risk, bleeding risk, anatomy, procedural safety, and comorbidity burden.
- Open Access
- 18 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5645
Impact of Resuscitation Status and Cardiac Arrest Location on Survival and Neurological Outcomes in Acute Coronary Syndrome Patients Undergoing Coronary Angiography
Background: Cardiac arrest complicating acute coronary syndrome (ACS) is associated with high mortality and neurological morbidity despite advances in percutaneous coronary intervention (PCI) and post-resuscitation care. This study evaluated clinical outcomes in ACS patients presenting with cardiac arrest undergoing invasive coronary angiography, with particular focus on resuscitation status before catheterization and location of cardiac arrest. Methods: A retrospective analysis of 15,595 ACS patients undergoing coronary angiography between 2014 and 2025 identified two cohorts. The first cohort included 131 patients stratified according to mechanical cardiac activity upon arrival to the catheterization laboratory: previously resuscitated patients (RES, n = 109) and patients in refractory cardiac arrest requiring automatic resuscitation devices (ARD, n = 22). The second cohort included 159 patients grouped by arrest location: out-of-hospital (OHCA, n = 83), in-hospital (IHCA, n = 48), and catheterization laboratory cardiac arrest (CLCA, n = 28). The primary outcomes were in-hospital mortality and neurological status after resuscitation. Results: In-hospital mortality was significantly higher in the ARD group compared with the RES group (86.4% vs. 39.4%, p < 0.001). Survivors in the RES group more frequently achieved favorable neurological recovery (66.2%). Mean resuscitation duration and admission lactate levels were significantly greater in the ARD group (66.1 vs. 21.9 min, p < 0.001; 10.7 vs. 7.7 mmol/L, p = 0.006). According to arrest location, mortality was highest in the CLCA group (78.6%), followed by IHCA (60.4%) and OHCA (39.8%) (p < 0.001). Despite high mortality, all surviving CLCA patients had favorable neurological outcomes. Culprit coronary vessel distribution was not associated with mortality or neurological outcome. Conclusions: In ACS patients with cardiac arrest, ongoing refractory arrest during coronary angiography and cardiac arrest occurring in the catheterization laboratory were associated with markedly increased mortality. Successful resuscitation prior to catheterization was associated with significantly better survival and neurological recovery.
- 18 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5645
Open AccessImpact of Resuscitation Status and Cardiac Arrest Location on Survival and Neurological Outcomes in Acute Coronary Syndrome Patients Undergoing Coronary Angiography
Background: Cardiac arrest complicating acute coronary syndrome (ACS) is associated with high mortality and neurological morbidity despite advances in percutaneous coronary intervention (PCI) and post-resuscitation care. This study evaluated clinical outcomes in ACS patients presenting with cardiac arrest undergoing invasive coronary angiography, with particular focus on resuscitation status before catheterization and location of cardiac arrest. Methods: A retrospective analysis of 15,595 ACS patients undergoing coronary angiography between 2014 and 2025 identified two cohorts. The first cohort included 131 patients stratified according to mechanical cardiac activity upon arrival to the catheterization laboratory: previously resuscitated patients (RES, n = 109) and patients in refractory cardiac arrest requiring automatic resuscitation devices (ARD, n = 22). The second cohort included 159 patients grouped by arrest location: out-of-hospital (OHCA, n = 83), in-hospital (IHCA, n = 48), and catheterization laboratory cardiac arrest (CLCA, n = 28). The primary outcomes were in-hospital mortality and neurological status after resuscitation. Results: In-hospital mortality was significantly higher in the ARD group compared with the RES group (86.4% vs. 39.4%, p < 0.001). Survivors in the RES group more frequently achieved favorable neurological recovery (66.2%). Mean resuscitation duration and admission lactate levels were significantly greater in the ARD group (66.1 vs. 21.9 min, p < 0.001; 10.7 vs. 7.7 mmol/L, p = 0.006). According to arrest location, mortality was highest in the CLCA group (78.6%), followed by IHCA (60.4%) and OHCA (39.8%) (p < 0.001). Despite high mortality, all surviving CLCA patients had favorable neurological outcomes. Culprit coronary vessel distribution was not associated with mortality or neurological outcome. Conclusions: In ACS patients with cardiac arrest, ongoing refractory arrest during coronary angiography and cardiac arrest occurring in the catheterization laboratory were associated with markedly increased mortality. Successful resuscitation prior to catheterization was associated with significantly better survival and neurological recovery.
- Open Access
- 18 February 2025
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 32 (1) , 126-131
Rescue Strategy in Cardiogenic Shock: Emergency Transcatheter Aortic Valve Implantation for Failed Bioprosthetic Valve – Case Report
Background: Transcatheter aortic valve implantation (TAVI) has emerged as an essential therapeutic intervention for patients with severe aortic valve disease, providing a less invasive alternative to traditional surgery, particularly in high-risk individuals. TAVI is also increasingly utilized as a valve-in-valve strategy in cases of a bioprosthetic valve failure. However, data on the efficacy of TAVI in the context of a hemodynamic collapse remain limited.Methods: This report represents a young, high-risk patient with a failed bioprosthetic valve and cardiogenic shock treated successfully with TAVI.Results: Emergency TAVI using a Medtronic Evolut Pro+ device achieved rapid hemodynamic stabilization and favorable post-procedural clinical and functional outcomes. Intermittent complete atrioventricular block necessitated the implantation of a permanent pacemaker.Conclusions: This case highlights the potential of TAVI as a safe and effective intervention in critical clinical scenarios. Emergency TAVI is a viable therapeutic intervention for patients with failed surgical bioprostheses presenting with cardiogenic shock.
- 18 February 2025
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 32 (1) , 126-131
Open AccessRescue Strategy in Cardiogenic Shock: Emergency Transcatheter Aortic Valve Implantation for Failed Bioprosthetic Valve – Case Report
Background: Transcatheter aortic valve implantation (TAVI) has emerged as an essential therapeutic intervention for patients with severe aortic valve disease, providing a less invasive alternative to traditional surgery, particularly in high-risk individuals. TAVI is also increasingly utilized as a valve-in-valve strategy in cases of a bioprosthetic valve failure. However, data on the efficacy of TAVI in the context of a hemodynamic collapse remain limited.Methods: This report represents a young, high-risk patient with a failed bioprosthetic valve and cardiogenic shock treated successfully with TAVI.Results: Emergency TAVI using a Medtronic Evolut Pro+ device achieved rapid hemodynamic stabilization and favorable post-procedural clinical and functional outcomes. Intermittent complete atrioventricular block necessitated the implantation of a permanent pacemaker.Conclusions: This case highlights the potential of TAVI as a safe and effective intervention in critical clinical scenarios. Emergency TAVI is a viable therapeutic intervention for patients with failed surgical bioprostheses presenting with cardiogenic shock.
- 11 November 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (2) , 292-300
Three‐Year Clinical and Hemodynamic Evaluation of the Hydra Self‐Expanding Transcatheter Aortic Valve in Patients With Severe Aortic Stenosis
Background: The Hydra CE study revealed 1‐year favorable efficacy of TAVR, showing a large effective orifice area (EOA), low gradient, and acceptable complication rates.Aims: We evaluated the 3‐year clinical and hemodynamic outcomes of Hydra self‐expanding transcatheter aortic valve (manufactured by Vascular Innovations Co Ltd, Nonthaburi, Thailand; a subsidiary of Sahajanand Medical Technologies Limited, India) in patients with symptomatic severe aortic stenosis at high or extremely high surgical risk.Methods: The Hydra CE study was a prospective, multicenter, single‐arm study. A total of 157 patients were enrolled in the study, out of whom 54 patients from two centers (Lithuania and Poland) had provided consent for long‐term follow‐up at recruitment, with a planned 5‐year follow‐up period. The primary endpoint was all‐cause mortality, and patients were followed up for up to 3 years, with an assessment of clinical and echocardiographic outcomes.Results: Among the 54 patients, the average age was 81.0 ± 4.1 years. The mean STS score was 3.2 ± 2.0%. At 3 years, all‐cause mortality had occurred in 14.8% of patients, including 3.7% cardiovascular deaths and 1.9% device‐related deaths. There was a progressive enhancement in EOA that is, 0.68 ± 0.15 cm2 at baseline to 1.97 ± 0.52 cm2 at 3 years (p < 0.001) as well as significant improvement in the mean aortic valve gradient that is, 53.4 ± 14.24 mmHg at baseline to 8.6 ± 2.80 mmHg at 3 years (p < 0.001). New permanent pacemaker implantation rates up to 3‐year follow‐up was 12.9%.Conclusion: The 3‐year results of the Hydra CE study demonstrated consistent improvements in hemodynamics over time. The study also revealed favorable safety and efficacy trends, along with low occurrences of new permanent pacemaker implantations and paravalvular leaks.
- 11 November 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (2) , 292-300
Three‐Year Clinical and Hemodynamic Evaluation of the Hydra Self‐Expanding Transcatheter Aortic Valve in Patients With Severe Aortic Stenosis
Background: The Hydra CE study revealed 1‐year favorable efficacy of TAVR, showing a large effective orifice area (EOA), low gradient, and acceptable complication rates.Aims: We evaluated the 3‐year clinical and hemodynamic outcomes of Hydra self‐expanding transcatheter aortic valve (manufactured by Vascular Innovations Co Ltd, Nonthaburi, Thailand; a subsidiary of Sahajanand Medical Technologies Limited, India) in patients with symptomatic severe aortic stenosis at high or extremely high surgical risk.Methods: The Hydra CE study was a prospective, multicenter, single‐arm study. A total of 157 patients were enrolled in the study, out of whom 54 patients from two centers (Lithuania and Poland) had provided consent for long‐term follow‐up at recruitment, with a planned 5‐year follow‐up period. The primary endpoint was all‐cause mortality, and patients were followed up for up to 3 years, with an assessment of clinical and echocardiographic outcomes.Results: Among the 54 patients, the average age was 81.0 ± 4.1 years. The mean STS score was 3.2 ± 2.0%. At 3 years, all‐cause mortality had occurred in 14.8% of patients, including 3.7% cardiovascular deaths and 1.9% device‐related deaths. There was a progressive enhancement in EOA that is, 0.68 ± 0.15 cm2 at baseline to 1.97 ± 0.52 cm2 at 3 years (p < 0.001) as well as significant improvement in the mean aortic valve gradient that is, 53.4 ± 14.24 mmHg at baseline to 8.6 ± 2.80 mmHg at 3 years (p < 0.001). New permanent pacemaker implantation rates up to 3‐year follow‐up was 12.9%.Conclusion: The 3‐year results of the Hydra CE study demonstrated consistent improvements in hemodynamics over time. The study also revealed favorable safety and efficacy trends, along with low occurrences of new permanent pacemaker implantations and paravalvular leaks.
- Open Access
- 19 February 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (3) , 100281
A Comparative Study of Transcatheter Aortic Valve Implantation Views for Two Different Self-Expanding Aortic Valves
- 19 February 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (3) , 100281
Open AccessA Comparative Study of Transcatheter Aortic Valve Implantation Views for Two Different Self-Expanding Aortic Valves
- Open Access
- 21 December 2022
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 101 (2) , 431-441
Impact of implantation technique on conduction disturbances for TAVR with the self‐expanding portico/navitor valve
Background: Use of a right−left (R−L) cusp overlap view for transcatheter aortic valve replacement (TAVR) with self‐expanding valves has recently been proposed aiming to reduce permanent pacemaker implantation (PPMI). An objective, data‐driven explanation for this observation is missing.Aims: To assess the impact of different implantation techniques on the risk of PPMI following TAVR with the Portico/NavitorTM transcatheter heart valve (THV; Abbott).Methods: A TAVR‐population treated with Portico/NavitorTM had the THV implanted in a right versus left anterior oblique (RAO/LAO) fluoroscopic view with no parallax in the delivery system. The impact of these different implantation views on the spatial relationship between THV and native aortic annulus and the risk of conduction disturbances and PPMI after TAVR was studied.Results: A total of 366 matched TAVR patients were studied: 183 in the RAO group and 183 in the LAO group. The degree of aortic annulus plane tilt was significantly smaller in the RAO versus LAO group (median: 0° vs. 23°, p < 0.001), with no plane tilt in 105 out of 183 cases (57.3%) in the RAO group. At 30 days after TAVR, the overall PPMI and guideline‐directed PPMI rates were 12.6% versus 18.0% (p = 0.15) and 8.2% versus 15.3% (p = 0.04) in the RAO versus LAO group, respectively.Conclusions: Use of a R−L cusp overlap (RAO‐caudal) view for implantation of the Portico/NavitorTM valve results in less tilt of the native aortic annulus plane and a clear trend toward a lower 30‐day PPMI rate as compared to TAVR using the conventional LAO implantation view.
- 21 December 2022
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 101 (2) , 431-441
Open AccessImpact of implantation technique on conduction disturbances for TAVR with the self‐expanding portico/navitor valve
Background: Use of a right−left (R−L) cusp overlap view for transcatheter aortic valve replacement (TAVR) with self‐expanding valves has recently been proposed aiming to reduce permanent pacemaker implantation (PPMI). An objective, data‐driven explanation for this observation is missing.Aims: To assess the impact of different implantation techniques on the risk of PPMI following TAVR with the Portico/NavitorTM transcatheter heart valve (THV; Abbott).Methods: A TAVR‐population treated with Portico/NavitorTM had the THV implanted in a right versus left anterior oblique (RAO/LAO) fluoroscopic view with no parallax in the delivery system. The impact of these different implantation views on the spatial relationship between THV and native aortic annulus and the risk of conduction disturbances and PPMI after TAVR was studied.Results: A total of 366 matched TAVR patients were studied: 183 in the RAO group and 183 in the LAO group. The degree of aortic annulus plane tilt was significantly smaller in the RAO versus LAO group (median: 0° vs. 23°, p < 0.001), with no plane tilt in 105 out of 183 cases (57.3%) in the RAO group. At 30 days after TAVR, the overall PPMI and guideline‐directed PPMI rates were 12.6% versus 18.0% (p = 0.15) and 8.2% versus 15.3% (p = 0.04) in the RAO versus LAO group, respectively.Conclusions: Use of a R−L cusp overlap (RAO‐caudal) view for implantation of the Portico/NavitorTM valve results in less tilt of the native aortic annulus plane and a clear trend toward a lower 30‐day PPMI rate as compared to TAVR using the conventional LAO implantation view.
- 2 April 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 40, 120-122
TAVR With the Novel Navitor Titan™ Transcatheter Heart Valve to Treat Aortic Stenosis Patients With Large Aortic Annuli
- 2 April 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 40, 120-122
TAVR With the Novel Navitor Titan™ Transcatheter Heart Valve to Treat Aortic Stenosis Patients With Large Aortic Annuli
- 18 March 2022
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 75 (4) , 16S
Smart and Sensing Endovascular Robot Sentante
- 18 March 2022
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 75 (4) , 16S
Smart and Sensing Endovascular Robot Sentante
- Open Access
Increase of Myocardial Ischemia Time and Short-Term Prognosis of Patients with Acute Myocardial Infarction during the First COVID-19 Pandemic Wave
Background and objectives: early reports showed a decrease in admission rates and an increase in mortality of patients with acute myocardial infarction (AMI) during the first wave of COVID-19 pandemic. We sought to investigate whether the COVID-19 pandemic and associated lockdown had an impact on the ischemia time and prognosis of patients suffering from AMI in the settings of low COVID-19 burden. Materials and Methods: we conducted a retrospective data analysis from a tertiary center in Lithuania of 818 patients with AMI. Data were collected from 1 March to 30 June in 2020 during the peri-lockdown period (2020 group; n = 278) and compared to the same period last year (2019 group; n = 326). The primary study endpoint was all-cause mortality during 3 months of follow-up. Secondary endpoints were heart failure severity (Killip class) on admission and ischemia time in patients with acute ST segment elevation myocardial infarction (STEMI). Results: there was a reduction of 14.7% in admission rate for acute myocardial infarction (AMI) during the peri-lockdown period. The 3-month mortality rate did not differ significantly (6.9% in 2020 vs. 10.5% in 2019, p = 0.341 for STEMI patients; 5.3% in 2020 vs. 2.6% in 2019, p = 0.374 for patients with acute myocardial infarction without ST segment elevation (NSTEMI)). More STEMI patients presented with Killip IV class in 2019 (13.5% vs. 5.5%, p = 0.043, respectively). There was an increase of door-to-PCI time (54.0 [42.0–86.0] in 2019; 63.5 [48.3–97.5] in 2020, p = 0.018) and first medical contact (FMC)-to-PCI time (101.0 [82.5–120.8] in 2019; 115 [97.0–154.5] in 2020, p = 0.01) during the pandemic period. Conclusions: There was a 14.7% reduction of admissions for AMI during the first wave of COVID-19. FMC-to-PCI time increased during the peri-lockdown period, however, it did not translate into worse survival during follow-up.
Open AccessIncrease of Myocardial Ischemia Time and Short-Term Prognosis of Patients with Acute Myocardial Infarction during the First COVID-19 Pandemic Wave
Background and objectives: early reports showed a decrease in admission rates and an increase in mortality of patients with acute myocardial infarction (AMI) during the first wave of COVID-19 pandemic. We sought to investigate whether the COVID-19 pandemic and associated lockdown had an impact on the ischemia time and prognosis of patients suffering from AMI in the settings of low COVID-19 burden. Materials and Methods: we conducted a retrospective data analysis from a tertiary center in Lithuania of 818 patients with AMI. Data were collected from 1 March to 30 June in 2020 during the peri-lockdown period (2020 group; n = 278) and compared to the same period last year (2019 group; n = 326). The primary study endpoint was all-cause mortality during 3 months of follow-up. Secondary endpoints were heart failure severity (Killip class) on admission and ischemia time in patients with acute ST segment elevation myocardial infarction (STEMI). Results: there was a reduction of 14.7% in admission rate for acute myocardial infarction (AMI) during the peri-lockdown period. The 3-month mortality rate did not differ significantly (6.9% in 2020 vs. 10.5% in 2019, p = 0.341 for STEMI patients; 5.3% in 2020 vs. 2.6% in 2019, p = 0.374 for patients with acute myocardial infarction without ST segment elevation (NSTEMI)). More STEMI patients presented with Killip IV class in 2019 (13.5% vs. 5.5%, p = 0.043, respectively). There was an increase of door-to-PCI time (54.0 [42.0–86.0] in 2019; 63.5 [48.3–97.5] in 2020, p = 0.018) and first medical contact (FMC)-to-PCI time (101.0 [82.5–120.8] in 2019; 115 [97.0–154.5] in 2020, p = 0.01) during the pandemic period. Conclusions: There was a 14.7% reduction of admissions for AMI during the first wave of COVID-19. FMC-to-PCI time increased during the peri-lockdown period, however, it did not translate into worse survival during follow-up.
- Open Access
- 22 September 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8
Intravascular Lithotripsy-Assisted Transfemoral TAVI: The Copenhagen Experience and Literature Review
Transcatheter aortic valve implantation (TAVI) is currently an established therapy for elderly patients with symptomatic severe aortic valve stenosis across all surgical risk categories. Access is an important aspect when planning for and performing TAVI. The superiority of a transfemoral (TF) approach compared to a transthoracic (transapical, direct aortic) approach has been demonstrated in several studies. Recently, the introduction of intravascular lithotripsy (IVL) has made it possible to treat patients with calcified iliofemoral disease by TF approach. This article aimed to provide a comprehensive overview on the following aspects: (1) preprocedural planning for IVL-assisted TF-TAVI; (2) procedural aspects in IVL-assisted TF-TAVI; (3) outcomes of IVL-assisted TF-TAVI in an experienced TAVI center; and (4) literature review and discussion of this new emerging approach.
- 22 September 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8
Open AccessIntravascular Lithotripsy-Assisted Transfemoral TAVI: The Copenhagen Experience and Literature Review
Transcatheter aortic valve implantation (TAVI) is currently an established therapy for elderly patients with symptomatic severe aortic valve stenosis across all surgical risk categories. Access is an important aspect when planning for and performing TAVI. The superiority of a transfemoral (TF) approach compared to a transthoracic (transapical, direct aortic) approach has been demonstrated in several studies. Recently, the introduction of intravascular lithotripsy (IVL) has made it possible to treat patients with calcified iliofemoral disease by TF approach. This article aimed to provide a comprehensive overview on the following aspects: (1) preprocedural planning for IVL-assisted TF-TAVI; (2) procedural aspects in IVL-assisted TF-TAVI; (3) outcomes of IVL-assisted TF-TAVI in an experienced TAVI center; and (4) literature review and discussion of this new emerging approach.